Do "biobetters" require their own regulatory pathway?
This article was originally published in SRA
Executive Summary
There are many opportunities for improving biological medicines that have been approved over the past decade and regulatory processes must be flexible if they are not to deter the incremental development of these "biobetters", says Cecil Nick.